Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Neoadjuvant Treatment of HER2-Positive Breast Cancer (AVATAXHER)
NCT01142778Phase 2Completed
- Sponsor
- Roche
- Start
- May 2010
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in HER2-positive breast cancer (3 arms), sponsored by Roche. Primary endpoint: Pathological Complete Response according to Chevallier's Classification at 18 weeks. Started May 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT01142778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01142778.